Identifying new cell death and inflammatory pathways

Identifying new cell death and inflammatory pathways

Project details

Our laboratory investigates how genetically encoded cell death signalling pathways influence inflammatory responses in hereditary and sterile inflammatory conditions (Vince and Silke, Cell Mol Life Sci 73(11-12):2349).

We have previously shown how targeted anti-cancer therapeutics, or genetic mutations, can sensitise cells to death and trigger pathological inflammation by causing a profound deficiency in Inhibitor of Apoptosis (IAP) protein levels (Vince et al., Cell 2007 131(4):682; Lawlor et al., Cell Reports 2017., 20(3):668).

Using CRISPR gene editing technology, this project will now screen for the physiological pathways, and novel genes, that modulate IAP levels and programmed cell death signalling. This will help us define how distinct cell death signalling cascades can drive autoinflammation, but also be therapeutically manipulated to induce cancer killing.

About our research group

Our laboratory studies the molecules that govern the often-connected processes of cell death and inflammation. These processes normally protect against microbial infection, and allow tissue repair. Loss of control of cell death and inflammation underpins diseases such as sepsis, rheumatoid arthritis and cancer. Our goal is to understand how cell death and inflammation are controlled, as a basis for new treatments for these diseases.


Dr James Vince

Dr James Vince in a laboratory
Laboratory Head
Kate Lawlor in the lab
Inflammation division

Professor David Vaux

David Vaux
Deputy Director and Joint Division Head

Project Type: